Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MRV-MNP
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $43.0 million
Deal Type : Funding
Micron Biomedical Secures $43 Million to Accelerate Vaccine Technology Trial
Details : The grant will support Micron’s efforts in increasing access to measles-rubella vaccine, MRV-MNP, and the ongoing manufacturing scale-up efforts and activities to support a phase 2 trial in infants.
Product Name : MRV-MNP
Product Type : Vaccine
Upfront Cash : Undisclosed
January 07, 2025
Lead Product(s) : MRV-MNP
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $43.0 million
Deal Type : Funding
Reset All
